BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations

Summary

BridgeBio's Attruby is showing strong commercial performance in transthyretin amyloidosis, while competitor Alnylam lowered full-year sales guidance for its competing drug Amvuttra.